TAK-188 / Takeda - LARVOL DELTA

TAK-188, an antibody-drug conjugate with a novel amanitin payload, disrupts immune suppression and leads to potent anti-tumor immunity through selective depletion of CCR8+ intratumoral regulatory T-cells (AACR 2026) - P1/2 | "In conclusion, TAK-188 robustly depletes CCR8+ cells both in vitro and in vivo and demonstrates anti-tumor activity as a single agent in nonclinical models. Based on this promising preclinical data, a Phase 1 study of TAK-188 has been opened (NCT07205718)."

ADC • IO biomarker • Oncology • Solid Tumor • CCR8 • CD4 • CD8

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors (clinicaltrials.gov) - P1/2 | N=223 | Recruiting | Sponsor: Takeda | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors (clinicaltrials.gov) - P1/2 | N=223 | Not yet recruiting | Sponsor: Takeda

New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck